What causes HAE

There are two different subtypes(2) of HAE based on the underlying genetic defect in the control of the blood protein C1-esterase inhibitor:

Type I HAE: This subtype is characterized by decreased levels of functional C1-INH protein. About 80-85% of patients suffer from this form of the disease.

Type II HAE: This type is associated with normal or increased levels of a dysfunctional C1-INH protein resulting in reduced levels of C1-INH activity.

Type III HAE: Recently a type III has been postulated: HAE type III arises independently of a C1-INH deficiency. It is relatively rare and primarily affects women. In some patients a mutation of factor XII was found.(15, 16-18)

Hereditary angioedema of type I and type II is caused by a defect (mutation) in the gene responsible for producing the protein C1 esterase inhibitor (C1-INH). Unlike other hereditary diseases, the healthy gene cannot compensate for the defect in the other gene in patients with HAE. Therefore, a child has a 50% chance of developing HAE if one parent has the gene mutation.(2,14)

Under normal conditions, C1-INH regulates the body’s production of bradykinin, a locally acting hormone that plays an important role in the control of the dilation (widening) and permeability of blood vessels – for example, in response to an injury or infection. If the C1-INH is not functioning properly or if its concentration is decreased, bradykinin is released excessively resulting in local swellings (edema).

Besides the contact system, C1-INH is also involved in the so called complement system which is part of the immune defense. As in the contact system, an external stimulus, for example a foreign body or microbe, triggers a reaction cascade which aims to eliminate the alien.

The cascade starts with the protein C1, whose direct counterpart is C1-INH. C1 is activated as soon as the immune system detects a foreign body, although the process is also self-activating to a lesser extent. Activated C1 activates a series of other factors in the complement system resulting in the elimination of the pathogen.

Infections, injuries, operations or stress(8) may lead to consumption of C1-INH and may thus result in elevation of bradykinin levels with subsequent edema formation. Drugs that lower blood pressure (ACE inhibitors) can also cause edema: by inhibiting the degradation of bradykinin its level is increased.

The role of bradykinin

Bradykinin is a naturally occurring peptide hormone that consists of nine amino acids and is formed locally in tissue. It is involved in the mediation of pain in the event of injury or inflammation. It increases the permeability of the vessels, dilates the blood vessels and causes smooth muscle to contract. In hereditary angioedema, bradykinin is the key mediator for the development of swelling.

It is part of a blood coagulation subsystem known as the contact system, which is regulated by C1-INH. If bradykinin levels are increased, fluids will pass through the vessel walls into the surrounding tissue causing the local swelling of an HAE attack.

After activation of the contact system by an external stimulus like an injury, a complex cascade of different steps follows ending up in the release of bradykinin. Main factors within the contact system are the factor XII and kallikrein.

Finally, after binding to the bradykinin receptor, bradykinin triggers a series of reactions in the tissues(19-23):

• Bradykinin increases the permeability of the vessels (vascular permeability), which allows liquid to pass into the tissues and therefore causes edema.

• Bradykinin widens the blood vessels (vasodilatation) and lowers blood pressure.

• Bradykinin causes the smooth muscle in the tissues to contract, producing cramps and pain.

C1-INH can normally inhibit (stop) the reaction cascade at two points: by preventing self-activation of factor XII and by inhibiting the release of bradykinin from HMW kininogen. In case of C1-INH deficiency release of bradykinin is no longer efficiently controlled. Bradykinin levels increase and edema develops.

News

Thu, 2014-11-06

BioCryst Reports Third Quarter 2014 Financial Results

Thu, 2014-11-06

Salix Pharmaceuticals Reports 3Q2014 Results

Wed, 2014-11-05

Pharming Confirms Milestone Payment From Salix Pharmaceuticals

Mon, 2014-11-03

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930

Mon, 2014-11-03

Launch of Ruconest in the U.S. for the Treatment of Acute HAE Attacks

Thu, 2014-10-30

Pharming Reports On Financial Results For The First Nine Months Of 2014

Newsletter Teaser ( In News Section on Homepage )

Newsletter

Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.

Sign up for HAEi Newsletter and register at the same time.


Join our Facebook group - and follow HAEi on Twitter

Facebook logo SFacebook logo STwitter logo STwitter logo S

  

Events

Thu, 2015-05-28 13:00 - Sun, 2015-05-31 14:00

9th C1 Inhibitor Deficiency Workshop

Venue: Danubius Thermal Hotel Margitsziget, Margitsziget, 1133 Budapest, Hungary
Language: English

It is our great pleasure to invite you to the 9th C1-INH Deficiency Workshop. This event has a history of many years, as well as its nature and objectives are familiar to many of us. Nevertheless, given the continued interest from first-time attendees, we would like to introduce the Workshop for them in brief, as follows.

This conference focuses on bradykinin-mediated angioedemas, and particularly on the types resulting from C1-inhibitor deficiency. The topics of this four-day long event cover a wide range of subjects.

Read more about the workshop here.

..continue
Fri, 2015-02-20 10:00 - Tue, 2015-02-24 16:00

AAAAI - Annual Meeting 2015

Venue: Houston, TX, United States of America
Language: English

Mark your calendars and head to Houston, Texas for the premier event in allergy/immunology. You will be able to earn CME/CE, learn about cutting-edge research and enrich your networking connections at the 2015 AAAAI Annual Meeting, February 20-24.

For more information please visit: AAAAI 2015
..continue
Sat, 2014-12-06 09:00 - Tue, 2014-12-09 15:00

WAO International Scientific Conference 2014

Venue: SulAmérica Convention Center, Av Paulo de Frontin, 1 - New City, Centro Rio de Janeiro - RJ, Brazil
Language: English

Advancing the borders of allergy: From treatment to prevention by targeting the environment, infections and the susceptible patient

We are delighted to welcome you to participate in the WAO International Scientific Conference 2014 (WISC 2014) and the XLI Annual Congress of the Brazilian Association of Allergy and Immunology (ASBAI) in Rio de Janeiro, Brazil, 6-9 December 2014.

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org